BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33142237)

  • 1. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
    Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
    Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
    Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
    Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Tang Y; Zheng Y; Hu X; Zhao H; Cui S
    J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
    Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
    Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282.
    Verma MK; Samant C; Kale R; Patra S; Mahajan N; Gholve MK; Marisetti A; Sunkara B; Naik A; Shingare M; Reddy M; Bokare AM; Akarte A; Koul S; Nigade PB; Patil VB; Modi D; Ahirrao P; Pawar S; Kuldharan S; Dinchhana L; Mehta M; Gundu J; Jana N; Vidhate P; Mahangare SJ; Shukla MR; Goel RN; Bhonde M; Kamboj RK; Palle VP
    Biochem Biophys Res Commun; 2022 Dec; 637():267-275. PubMed ID: 36410276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors.
    Wang NY; Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127479. PubMed ID: 32784091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
    Xie C; He Y; Zhen M; Wang Y; Xu Y; Lou L
    Cancer Sci; 2017 Jul; 108(7):1476-1484. PubMed ID: 28418085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
    Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
    Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
    Moreno O; Wood J
    Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.